

Serial No.: 10/738,938

Attorney Docket No.: 801204-0003

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Inventor(s) : Raul G. Barletta and Zhengyu Feng

Serial No. : 10/738,938

Filing Date : December 17, 2003

Title : RECOMBINANT MYCOBACTERIA

OVEREXPRESSIING D-ALANINE LIGASE GENE

AND USES THEREFORE

Group/Art Unit : 1652

Examiner : Not Yet Assigned

Confirmation No. : 8745

Atty. Docket No. : 801204-0003

INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. § 1.97(b)

Mail Stop Amendment Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Dear Sir:

In accordance with 37 C.F.R. § 1.56 and § 1.97(b), the references listed on the attached Form PTO/SB/08A (Substitute for Form 1449A-B/PTO) are being brought to the attention of the Examiner for consideration in connection with the examination of the above-identified patent application. Copies of the cited documents are enclosed. Submission of these references is not an admission that the references constitute prior art.

Applicants respectfully request that these references be made of record in the above-identified application and considered by the Examiner during prosecution of the application.

It is respectfully submitted that the present invention as claimed is patentable over the listed references.

Certificate of Mailing Under 37 C.F.R. 1.8

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on:

Date: 14 2004
Signature: 1500 Sunday
Printed Name: 1500 Sunday

The Director is hereby authorized to charge any additional amount required, or credit any overpayment, to Deposit Account No. 19-4409.

Serial No.: 10/738,938 Attorney Docket No.: 801204-0003

This information disclosure statement is being filed within three months of the filing date of a national application other than a continued prosecution application under § 1.53(d) or before the mailing of a first Office Action on the merits. Accordingly, no fee is due.

Acknowledgment of receipt is respectfully requested.

Respectfully submitted,

By:

Nancy T. Morris, Reg. No. 42,017

STINSON MORRISON HECKER LLP

1201 Walnut, Suite 2800

Kansas City, MO 64106-2150

Telephone: (816) 842-8600 Facsimile: (816) 691-3495 Attorney for Applicant[s]

PTO/SB/08A (08-00) Approved for use through 10/31/2002. OMB 0651-0031 U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

December 17, 2003

Raul G. Barletta

801204-0003

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number. Complete if Known **Application Number:** 10/738,938

Filing Date:

Substitute for Form 1449A/PTO INFORMATION DISCLOSURE

Sheet

1

of 4

STATEMENT BY APPLICANT Group Art Unit: 1652 (use as many sheets as necessary) Not Yet Assigned **Examiner Name:**

First Named Inventor:

Attorney Docket Number:

U. S. PATENT DOCUMENTS U.S. Patent Document Pages, Columns, Lines Date of Publication of Name of Patentee or Applicant Examiner Cite Where Relevant Kind Code² Cited Document No.1 of Cited Document Passages or Relevant Initials* MM-DD-YYYY (if known) Number Figures Appear

FOREIGN PATENT DOCUMENTS								
Examiner Initials*	Cite No.1	Foreign Patent Document				Date of Publication of	Pages, Columns, Lines,	\sqcap
		Office ³	Number ⁴	Kind Code ⁵ (if known)	Name of Patentee or Applicant of Cited Document	Cited Document MM-DD-YYYY	Document Where Relevant	T 6
								-
								+-
		<u> </u>						<u> </u>
<u> </u>								╁
								\vdash
								\Box

Examiner	Date	
Signature	Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Unique citation designation number. 2 See attached Kinds of U.S. Patent Documents. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 6 Applicant is to place a check mark here if English language Translation

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

PTO/SB/08B (08-00)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for Form 1449B/PTO (Modified)

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet

of 4

Complete if Known				
Application Number:	10/738,938			
Filing Date:	December 17, 2003			
First Named Inventor:	Raul G. Barletta			
Group Art Unit:	1652			
Examiner Name:	Not Yet Assigned			
Attorney Docket Number:	801204-0003			

xaminer	Cite	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the	Τ_
nitials*	No.1	item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T
		FENG, ZHENGYU, and Barletta, Raúl, "Roles of Mycobacterium smegmatis D-Alanine:D-Alanine Ligase and	
		D-Alanine Racemase in the Mechanisms of Action of and Resistance to the Peptidoglycan Inhibitor D-	
		Cycloserine", Antimicrobial Agents and Chemotherapy. 2003, Vol. 47, No. 1, p. 283-291.	_
		CHACON, OFELIA, et al., "Mycobacterium smegmatis D-Alanine Racemase Mutants Are Not Dependent on	
		D-Alanine for Growth", Antimicrobial Agents and Chemotherapy. 2002, Vol. 46, No. 1, p. 47-54.	
		CÁCERES, NANCY E., et. al., "Overexpression of the D-Alanine Racemase Gene Confers Resistance to D-	
		Cycloserine in <i>Mycobacterium smegmatis</i> ", <i>Journal of Bacteriology</i> . Aug. 1997, Vol. 179, No. 16, p. 5046-	
		5055.	\perp
		ZHENGYU, FENG, et. al., "Mycobacterium smegmatis L-Alanine Dehydrogenase (Ald) Is Required for	
		Proficient Utilization of Alanine as a Sole Nitrogen Source and Sustained Anaerobic Growth", Journal of	
		Bacteriology. Sept. 2002, Vol. 184, No. 18, p. 5001-5010.	
		KAMOGASHIRA, TAKASHI and Takegata, Setsuko, "A Screening Method for Cell Wall Inhibitors Using a D-	
		Cycloserine Hypersensitive Mutant", <i>The Journal of Antibiotics</i> . June 1988, Vol. XLI, No. 6, p. 803-806.	
		STRYCH, ULRICH, et. al., "Characterization of the Alanine Racemases from Two Mycobacteria", FEMS	
		Microbiology Letters. 2001, Vol. 196, p. 93-98.	
		COPIÉ, VALÉRIE, et al., "Inhibition of Alanine Racemase by Alanine Phosphonate: Detection of an Imine	1
		Linkage to Pyridoxal 5' –Phosphate in the Enzyme-Inhibitor Complex by Solid-State ¹⁵ N Nuclear Magnetic	
		Resonance". <i>Biochemistry</i> , 1988, Vol. 27, p. 4966-4970.	
		HEATON, MICHAEL P., et. al, "Controlled Lysis of Bacterial Cells Utilizing Mutants with Defective Synthesis	
		of D-Alanine", Can. J. Microbiol., 1988, Vol. 34, p. 256-261.	
		PATCHETT, ARTHUR A., et. al., "Antibacterial Activities of Fluorovinyl- and Chlorovinylglycine and Several	T
		Derived Dipeptides", Antimicrobial Agents and Chemotherapy. Mar. 1988, Vol. 32, No. 3, p. 319-323.	
		LAMBERT MARY Research Committee of Recording Authorities All Committee of Recording Authorities All Committee of Recording Authorities Authorities All Committee of Recording Authorities All Committee of Recording Authorities Authoriti	t
		LAMBERT, MARY P., and Neuhaus, Francis C., "Mechanism of D-Cycloserine Action: Alanine Racemase from Escherichia coli W", <i>Journal of Bacteriology</i> . 1972, Vol. 110, No. 3, p. 978-987.	
	•	10.11 25016.10.10 561 17 , 5501.10.10 593. 1512, 151. 115, 116. 6, p. 615 561.	╄
		HOLS, PAXCAL, et. al, "Conversion of <i>Lactococcus Lactis</i> from Homolactic to Homoalanine Fermentation	
		through Metabolic Engineering", Nature Biotechnology. June 1999, Vol. 17, p. 588-592.	
		TAUCH, ANDREAS, et. al., "The Alanine Racemase Gene alr is an Alternative to Antibiotic Resistance Genes	
		in Cloning Systems for Industrial Corynebacterium Glutamicum Strains", Journal of Biotechnology. 2002, Vol.	
		99, p. 79-91.	_
		ARIAS, CESAR A., et. al, "Serine and Alanine Racemase Activities of VanT: a Protein Necessary for	
		Vancomycin Resistance in Enterococcus Gallinarum BM4174", Microbiology. 2000, Vol. 146, p. 1727-1734.	
		THOMPSON, ROBERT J., et. al, "Pathogenicity and Immunogenicity of a Listeria monocytogenes Strain That	
ļ		Requires D-Alanine for Growth", <i>Infection and Immunity</i> . Aug. 1998, Vol. 66, No.8, p. 3552-3561.	

1PE	
JUL 1 6 2004 8	HOLS, P., et. al., "The Alanine Racemase Gene is Essential for Growth of Lactobacillus plantarum", Journal of Bacteriology. June 1997, Vol. 179, No. 11, p. 3804-3807.
THE TRADE	NEIDHART, DAVID J., et. al., "X-ray Crystallographic Studies of the Alanine-specific Racemase from Bacillus stearothermophilus", The Journal of Biological Chemistry. 1987, Vol. 262, No. 32, p. 15323-15326.
MADE	BRAUNSTEIN, MIRIAM, et. al., "Genetic Methods for Deciphering Virulence Determinants of Mycobacterium tuberculosis", Virulence and Essential Gene Identification. 2002 p. 67-99.
	TYAGI, JAYA S. and Sharma, Deepak, "Mycobacterium smegmatis and Tuberculosis", TRENDS in Microbiology. February 2002, Vol. 10, No. 2, p. 68-69.
	DAVID, HUGO L., et. al., "Susceptibility of Mycobacterial D-Alanyl-D-Alanine Synthetase to D-Cycloserine", American Review of Respiratory Disease. 1969, Vol. 100, p. 579-581.
	NEUHAUS, FRANCIS C. "The Enzymatic Synthesis of D-Alanyl-D-alanine. I. Purification and Properties of D-Alanyl-D-Alanine Synthetase", <i>Journal of Biological Chemistry</i> . March 1962, Vol. 237, No. 3, p. 778-786.
	PETEROY, MARCY, et. al., "Characterization of a <i>Mycobacterium smegmatic</i> Mutant That Is Simultaneously Resistant to D-Cycloserine and Vancomycin", <i>Antimicrobial Agents and Chemotherapy</i> . June 2000, Vol. 44, No. 6, p. 1701-1704.
	MANNING, JAMES M., et. al., "Inhibition of Bacterial Growth by β-Chloro-D-Alanine", <i>Proc. Nat. Acad. Sci.</i> February 1974, Vol. 71, No. 2, p. 417-421.
	DAVID, SUZANA, "Synergic Activity of D-Cycloserine and β-Chloro-D-Alanine Against <i>Mycobacterium tuberculosis</i> ", Journal of Antimicrobial Chemotherapy. 2001, Vol. 47, p. 203-206.
	MARSHALL, C. GARY and Wright, Gerard D., "Dd1N from Vancomycin-Producing Amycolatopsis orientalis C329.2 Is a VanA Homologue with D-Alanyl-D-Lactate Ligase Activity", Journal of Bacteriology. Nov. 1998, Vol. 180, No. 21, p. 5792-5795.
	RASTOGI, NALIN, et. al., "Enhancement of Drug Susceptibility of <i>Mycobacterium avium</i> by Inhibitors of Cell Envelope Synthesis", <i>Antimicrobial Agents and Chemotherapy</i> . May 1990, Vol. 34, No. 5, p. 759-764.
	DUTKA-MALEN, SYLVIE, et. al., "Sequence of the vanC Gene of <i>Enterococcus gallinarum</i> BM4174 encoding a D-Alanine:D-Alanine Ligase-Related Protein Necessary for Vancomycin Resistance", <i>Gene.</i> 1992, Vol. 112, p. 53-58.
	BELANGER, AIMEE E. and Inamine, Julia M., "Genetics of Cell Wall Biosynthesis", <i>Molecular Genetics of Mycobacteria</i> . Hatfull, G.F. and Jacobs, W.R. (Eds.), ASM Press, Washington, D.C., 2000, p. 191-202.
	REITZ, RICHARD H., et. al., "The Biochemical Mechanisms of Resistance by Streptococci to the Antibiotics D-Cycloserine and O-Carbamyl-D-Serine", <i>Biochemistry</i> . Aug. 1967, Vol. 6, No. 8, p. 2561-2570.
	WALSH, CHRISTOPER T., "Enzymes in the D-Alanine Branch of Bacterial Cell Wall Peptidoglycan Assembly", Journal of Biological Chemistry. 1989, Vol. 264, No. 5, p. 2393-2396.
	DAVID, HUGO L., "Resistance to D-Cycloserine in the Tubercle Bacilli: Mutation Rate and Transport of Alanine in Parental Cells and Drug-Resistant Mutants", <i>Applied Microbiology</i> . May 1971, Vol;. 21, No. 5, p. 888-892
	ZYGMUNT, WALTER A., "Antagonism of D-Cycloserine Inhibition of Mycobacterial Growth By D-Alanine", J. Bacteriol. 1963, Vol. 85, p. 1217-1220.
	YEW, WING WAI, et. al., "Adverse Neurological Reactions in Patients with Multidrug-Resistant Pulmonary Tuberculosis After Coadministration of Cycloserine and Ofloxacin", <i>Clinical Infectious Diseases</i> . August 1993, Vol. 17, 288-289.

	KAUFMAN, DARRELL and Manley, William F., "A New Procedure for Determining DL Amino Acid Ratios in Fossels Using Reverse Phase Liquid Chromatography", 1998. <i>Quaternary Geochronology</i> , Vol. 17, p. 987-1000.	
NEUHAUS, FRANCIS C., "D-Cycloserine and O-Carbamyl-D-serine", Antibiotics - Vol. 1, Mechanism of Action. Gottlieb, D and Shaw, Paul D. (eds.), Springer-Verlag New YorK Inc., 1967, p. 40-83.		

Examiner	Date	
Signature	Considered	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.